Xtandi
(enzalutamide)Xtandi 40 MG Oral CapsuleXtandi 40 MG Oral Tablet
NO BOXED WARNING
Dosage & administration
XTANDI 160 mg administered orally once daily.
Patients receiving XTANDI should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
biomarker testing
Xtandi clinical details
Genetic testing requirements were obtained from the NCCN guidelines for each cancer type. drug label
Xtandi prescribing information
prior authorization
Xtandi prior authorization resources
Benefits investigation
Learn MoreBenefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
Learn MoreSome brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
pharmacy
Xtandi preferred pharmacy
financial assistance
Xtandi financial assistance options
Co-pay savings program
Learn MoreOverview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
Learn MoreOverview
- Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
- Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
- 100% free (outside of insurance)
Patient eligibility
- HCP must enroll patient
- May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
- Typically HCP assisted enrollment (via form)
Foundation programs
Learn MoreOverview
- Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
- These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
- Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
- Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
- Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Xtandi patient education
To share resource; ask patient to: 1.Pull out phone
2.Open camera
3.Scan QR code with camera
people also ask
Xtandi FAQs
How is the dosage of Xtandi?Xtandi is available in 3 dosages, including 40 mg Cap, 40 mg Tab and 80 mg Tab
What does Xtandi treat?Xtandi treats Prostatic Neoplasms
What is Xtandi made of?Xtandi contains enzalutamide which is a Androgen Receptor Inhibitor
How Is Xtandi Administered?Xtandi is administered as a Oral Pill
What Are The Xtandi Mechanism Of Action?Xtandi mechanism of action is Androgen Receptor Antagonists, Cytochrome P450 2C19 Inducers, Cytochrome P450 2C9 Inducers or Cytochrome P450 3A4 Inducers
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
